Study on psychoeducation enhancing results of adherence in patients with schizophrenia (SPERA-S): Study protocol for a randomized controlled trial by Petretto, D. R. et al.
TRIALS
Petretto et al. Trials 2013, 14:323
http://www.trialsjournal.com/content/14/1/323STUDY PROTOCOL Open AccessStudy on psychoeducation enhancing results of
adherence in patients with schizophrenia
(SPERA-S): study protocol for a randomized
controlled trial
Donatella Rita Petretto1*, Antonio Preti1, Carlo Zuddas1, Franco Veltro2, Marco Bruno Luigi Rocchi3, Davide Sisti3,
Valentina Martinelli4, Mauro Giovanni Carta5, Carmelo Masala1 and on behalf of the SPERA-S groupAbstract
Background: Poor adherence to pharmacotherapy negatively affects the course and the outcome of
schizophreniaspectrum psychoses, enhancing the risk of relapse. Falloon and coworkers developed a
Psychoeducation Program aimed at improving communication and problem-solving abilities in patients and their
families. This study set out to evaluate changes in adherence to pharmacotherapy in patients diagnosed with
schizophrenia-spectrum psychoses, by comparing one group exposed to the Falloon Psychoeducation Program
(FPP) with another group exposed to family supportive therapy with generic information on the disorders.
Methods: 340 patients diagnosed with schizophrenia and related disorders according to standardized criteria from
10 participating units distributed throughout the Italian National Health System (NHS), will be enrolled with 1:1
allocation by the method of blocks of randomized permutations. Patients will be reassessed at 6, 12 and 18 months
after start of treatment (duration: 6 months).
The primary objective is to evaluate changes in adherence to pharmacotherapy after psychoeducation. Adherence
will be assessed at three-month intervals by measuring blood levels of the primary prescribed drug using high
pressure liquid chromatography, and via the Medication Adherence Questionnaire and a modified version of the
Adherence Interview. Secondary objectives are changes in the frequency of relapse and readmission, as the main
indicator of the course of the disorder.
Enrolled patients will be allocated to the FPP (yes/no) randomly, 1:1, in a procedure controlled by the coordinating
unit; codes will be masked until the conclusion of the protocol (or the occurrence of a severe negative event). The
raters will be blind to treatment allocation and will be tested for blinding after treatment completion. Intention-to-
treat will be applied in considering the primary and secondary outcomes. Multiple imputations will be applied to
integrate the missing data. The study started recruitment in February 2013; the total duration of the study is 27
months.
Discussion: If the psychoeducation program proves effective in improving adherence to pharmacotherapy and in
reducing relapse and readmissions, its application could be proposed as a standard adjunctive psychosocial
treatment within the Italian NHS.
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first patient was randomized on 12 February 2013.
Keywords: Randomized controlled trial, Schizophrenia, Psychoeducation, Falloon’s method, Adherence to
pharmacotherapy, Family, CaregiverBackground
Schizophrenia and its related psychoses are severe mental
disorders with a high impact in terms of disability and poor
quality of life. The clinical course of schizophrenia is typic-
ally one of highly recurrent acute episodes with chronic im-
pairment of social, vocational and personal wellbeing [1-3].
Prevalence of schizophrenia in the general population is 0.5
to 1%, with a higher risk and poorer outcome among males
than females [4].
The costs for patients, their families and society are
huge, and largely generated by the direct cost of care,
especially hospitalization [5-7]. Even higher costs arise
from lost productivity (unemployment of patients and
absence from work by the relatives who care for them),
informal care, criminal justice service involvement, and
social security expenditure [8,9].
Poor adherence to therapy negatively impacts on the
course and the outcome of schizophrenia, enhancing the
risk of relapse, hospital admission and readmission, and
family burden [10]. Non-adherence to pharmacotherapy
in patients diagnosed with schizophrenia is 41 to 50%
[11,12] and is predictive of a higher risk of relapse and a
readmission rate up to five times higher than in adherent
patients [13].
Currently, pharmacotherapy is the most important
therapeutic intervention in the treatment of schizophrenia-
spectrum psychoses. Higher adherence to pharmacotherapy
is expected to favor a better course of the disorder, and
specifically to reduce the risk of relapse and readmis-
sion, both of which heavily increase the burden of the
disorder and are a great cause of distress, particularly
after compulsory admission.
In recent years, many educational programs have been
aimed at improve knowledge of the disorder, its symptoms,
course and outcome, and the availability of treatment,
and have focused specifically on the patients and their
families [14-17].
Psychoeducational programs were developed to improve
adherence to pharmacotherapy by reducing irrational
beliefs towards drugs and their side effects, increasing
tolerance to the inevitable and unwanted effects, and
promoting coping strategies and problem-solving skills
to help face everyday problems associated with the disorder.
Studies on the real effectiveness of these programs have
found protective effects against the risk of relapse and on
the probability of readmission, with medium effect-sizes:Cohen’s d = 0.18 (95% CI = 0.13 to 0.49) and d = 0.58
(95% CI = 0.27 to 0.89), respectively [16]. A 2011 meta-
analysis including 5,142 participants from 44 independent
trials conducted from 1998 to 2009 confirmed the effective-
ness of psychoeducation in reducing relapse and readmis-
sion [18]. Participants receiving psychoeducation were also
found to be more satisfied with mental health services and
reported a better quality of life.
More complex intervention models involve both the
patients and their families, because the disorder is
chronic from its onset and can cause a heavy burden on
the family: the patient is unlikely to preserve a reasonable
level of autonomy and independence without the support
of his/her relatives. For this reason, psychoeducation
programs involving the family are more likely to produce
positive results on the course of the disorder [16].
Falloon and co-workers were among the first to de-
velop a model of intervention in schizophrenia centered
on the psychoeducation of the patients and their families
[19,20]. Falloon’s model included sessions aimed at helping
patients and their families recognize early stressful events
and early indicators of the risk of stress-induced relapse;
sessions aimed at the development of optimal adherence to
pharmacotherapy; and sessions aimed at improving coping
strategies and problem solving in everyday life [20]. This
method proved effective following the first evaluation: at
the two-year follow-up, cumulative relapse rates markedly
differed between controls and the interventional group
(83% versus 17%, respectively), and family therapy according
to Falloon’s model resulted in fewer hospitalizations, im-
provement in patients’ social functioning, and lower levels
of family burden and distress [19]. Past studies on Falloon’s
model did not investigate adherence to pharmacotherapy in
detail but concentrated on the course of the disorder and,
specifically on the risk of relapse and readmission. Several
more studies confirmed the effectiveness of this method on
the risk of hospitalization, family burden and patient’s social
functioning [20] but did not report clear evidence of effects
on adherence, a result expected on the theoretical basis of
the model and supported in small-sample studies carried
out in specialized academic settings [21]. The results of
these latter studies cannot be extended to the General
Hospital Psychiatric Units (GHPUs) operating in the Italian
National Health System (INHS).
Currently, expert consensus guidelines assign family
psychoeducation a high second-line rating and recommend
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mental disorders [22]. In the INHS, family psychoeducation
is rarely provided to patients and their families, with the
exception of academic settings [23]. There is evidence of an
inverse relationship between the availability of community-
based mental health care and the need status of schizo-
phrenic patients: the fewer out-patient and rehabilitation
services available, the more unmet needs there were [24].
Improving the effectiveness of treatment offered to patients
who have been diagnosed with schizophrenia is also likely
to reduce the stigma of schizophrenia [25], which is barely
affected by the small increase in public understanding of
the biological correlates of mental illness [26].
Aims
This study specifically set out to investigate the effectiveness
of Falloon and co-workers’ Psychoeducation Program (FPP)
and to evaluate its feasibility as part of the standard care
setting provided by the INHS. The FPP will be compared
to a control group, and randomized to a treatment with
generic information on the disorders administered with
the same frequencies as the FPP (Generic Treatment (GT)).
We foresee that the FPP will be effective in improving
adherence to pharmacotherapy in the exposed group when
compared to the non-exposed group, and we also expect
that the FPP will reduce the risk of relapse and readmission
in the exposed group, by maintaining its effects at both six-
and twelve-month follow-ups. Positive results would imply
the importance of applying the FPP in all INHS settings,
and the need of exploring its potential in other classes
of psychosis, such as affective psychoses, which are also
burdened by high personal, family and social costs.
A secondary goal of the study is the production of a
manual to be used in the training and assessment of the
professional staff involved in the treatment of patients
diagnosed with schizophrenia-spectrum psychosis.
The primary outcome of the study, adherence to therapy,
will be measured through a triple approach: a scaled
self-report questionnaire, a four-query interview and, for
the first time, the blood levels of the primary prescribed
drug (to be measured by a specialized pharmacology unit
with extensive experience in this type of studies). In this
way, we will be able to validate the simpler instruments of
measurement, such as the self-report or interview, with an
objective, gold-standard method (blood levels of the thera-
peutic compound), a practice rarely used in past studies on
adherence to therapy in patients with psychosis [27]. If one
or both of the simpler, self-report instruments of assessment
prove to be valid enough to differentiate adherent from
non-adherent or partially adherent patients, the study will
produce add-on information on easy-to-be-administered
tools, to be generalized for future related studies.
The participating INHS centers are distributed across the
country: we foresee the participation of ten enrolling unitsfrom nine large administrative regions of north, central
and south Italy, to include both GHPUs and University
Psychiatric Clinics (UPCs), six of them already having
experience with the FPP. The heterogeneity of the par-
ticipating units can be seen as a limit of the study, when
considered in terms of intra-cluster variance (which we took
into account in statistical power analysis on sample size,
with appropriate corrections). However, it can represent an
advantage, too, allowing for the exploration of the feasibility
and effectiveness of the FPP in different settings, especially
those operating in GHPUs, which have traditionally been
exposed to a higher workload than academic centers where
the FPP has more often been tested thus far.
Methods/design
Overview
This study is supported by the Italian Medicines Agency
(Agenzia Italia del Farmaco) - grant for SPERA-S: Study
on Psychoeducation Enhancing Results of Adherence in
Schizophrenia (FARM892ZXE) (see Acknowledgements for
details on the contract of financing).
The institutional review boards of both the university
that coordinated the study and of the participating
centers approved the study’s protocol which complies
with the provisions of the 1995 Declaration of Helsinki
(as revised in Tokyo, 2004).
In this study, the FPP will be compared to a treatment
providing general information on psychosis GT adminis-
tered with the same frequency as the FPP. The study will
be randomized and blinded for the assessment: raters will
be not informed about whether patients are in the FPP
or GT groups. Inevitably, the therapists providing the
treatment will know their patients’ treatment status.
The study will enroll adult patients diagnosed with
psychosis in the spectrum of schizophrenia from ten
participating units distributed throughout INHS territory.
The sample will be randomized in an exposed group and
an unexposed group, with 340 patients overall enrolled,
with a 1:1 allocation ratio.
Eligibility criteria
Inclusion criteria
Patients will be enrolled when they have a diagnosis of
psychosis in the spectrum of schizophrenia according to
the International Classification of Diseases - tenth edition
(ICD-10: codes F20 to F29) and have been in contact with
the unit for at least 24 months; admitting ages vary from 18
to 55 years old. Enrolled patients will be randomly allocated
to FPP treatment (yes/no) with a rate 1:1, via a procedure
controlled by the coordinating unit; codes will be masked
until the conclusion of the protocol (or the occurrence
of a severe negative event). Randomization will be carried
out by the method of blocks of randomized permutations
(to preserve balancing between the exposed and the
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by location, due to the study’s multisite nature.
Exclusion criteria
Exclusion criteria are mental retardation or any severe
cognitive impairment; psychosis due to substance abuse
or to a medical condition; affective psychosis; co-morbid
substance dependence; patient does not understand Italian;
pharmacotherapy with depot. Inability or unwillingness to
provide informed consent are additional exclusion criteria
(see Table 1 for details).
Recruitment and baseline procedures
Patients will be enrolled in the clinical setting, which
includes both GHPUs and UPCs.
To rationalize the training and quality-control procedures
for the FPP and GT therapists (two for each participating
unit) and the assessors (one for each unit), a Training and
Quality Control Center will be established in Cagliari,
the site of the coordination unit. This Center will train the
assigned therapists in FPP and GT and will also train
the assessors in the administration of the psychometric
measures. On a regular six-month basis, the Center will
organize meetings to verify the course of the study.
The Coordination Center will manage the procedures
of treatment allocation and will coordinate the study,
the statistical analysis, the storage of data, the training of
the assessors involved in the patients’ evaluation and of the
therapists involved in the FPP and GT. The Coordination
Center with two units from the University of Cagliari
(Center for Research and Treatment in Mental Health and
Pharmacological Unit) will monitor data recording and
storage, quality assessment of FPP and GT, and quality
assessment of the training for assessors and therapists.
A Steering Committee (the principal investigator plus
another member of the Coordination Center, a member
from the Monitoring Unit, a member from the Statistics
Unit, and three members elected by the enrolling units)Table 1 Eligibility criteria
Inclusion criteria Diagnosis of psychosis in the spectrum of
schizophrenia (ICD-10: F20 to F29)
Contact with the unit for at least 24 months
Admitting ages varying from 18 to 55 years
Exclusion criteria Mental retardation, or any severe cognitive
impairment
Psychosis due to substance abuse or to a
medical condition
Co-morbid substance dependence
Patient does not understand Italian
Pharmacotherapy with depot
Inability or unwillingness to provide
informed consentwill coordinate the use of the database for publications.
A centralized laboratory (Pharmacological Unit, University
of Cagliari) will analyze the blood levels for drugs in the
samples received from all participating units.
Timing
In the first three months of the study, the Coordination
Center and all directors of the participating units will
check the organization of the study, the assessment
methodology, the training of the assessors and their
inter-rater agreement.
As far as the investigational trial is concerned, we fore-
see three months for the enrollment of the patients; six
months for the subsequent exposition to the FPP of the
patients allocated to treatment (the exposed group), or
same-length GT for the unexposed group; there will be
subsequent six-month and twelve-month follow-ups to
verify whether the immediate benefit of FPP, if any, is
maintained after the conclusion of the FPP treatment.
Patients will be evaluated at entry (t0), at the conclusion
of the treatment (both exposed and unexposed) (t1), after
six months of follow-up (t2) and after twelve months of
follow-up (t3). The final report will be made within six
months of the conclusion of the study, but initial reports
will be prepared six months after the start (see Figure 1).
Randomization procedures and bias-minimization methods
All patients will be randomized in the exposed (FPP) or the
unexposed (GT) group with a 1:1 allocation ratio in each
unit, as each unit is expected to participate in the en-
rollment of both groups. Randomization will be carried
out by the method of blocks of randomized permuta-
tions (to preserve balancing between the exposed and
the non-exposed groups). Randomization will be stratified
by location due to the multisite nature of the study.
Correctness of the randomization procedure will be moni-
tored at regular intervals.
Allocation concealment
Block size will be specified by the Coordination Center
and will not be revealed to any researcher or staff until
the end of the enrollment period.
Blinding
This study will implement a complete separation of
treatment and assessment to allow for a single blind design
of assessment. Therefore, therapists will not be involved in
the assessment of the treatment outcome, and raters will
not be allowed to hold treatment sessions. Patients will be
informed about their treatment allocation by the therapist,
and only therapists will receive information about group al-
location. Discussions about patients enrolled in the study
will be not allowed between raters and therapists, as per
instructions given during staff training.
Figure 1 Flowchart of participants during the trial.
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at the end of the study. Any unintentional disclosure of
the treatment condition will therefore be hopefully doc-
umented. Further, the raters will be asked to guess the
study condition of the patient after the end of the study.
Among all documented guesses, the rate of correct guesses
should not significantly differ from chance (that is, 50%).
The main outcome of the study is adherence to the
prescribed therapy, and one of the indicators is the
measurement of blood levels of the primary prescribed
drug, which is independent from the assessment carried
out by the raters. It is unlikely that any personal opinion
of the raters on the presumed superior effectiveness of the
FPP over GT will influence the measurement of blood
levels of the primary prescribed drug. However, we are in-
terested in knowing whether any bias might have occurred
in the blinding, whether by unintentional disclosure of the
treatment condition or because the personal opinion of
the raters led them to guess the patients’ allocation to the
treatment modality.
Planned interventions
The FPP aims at improving communication and problem-
solving abilities in patients and their families through
sessions focused on: assessment of the individual’s and the
family’s strengths, weaknesses, and goals; education about
schizophrenia and treatment; communication skills train-
ing; problem-solving training; and training to cope with
special problems [19]. Treatment sessions are provided on
a weekly basis for six months (one and a half hours foreach session). The first six sessions will be provided to
each individual family with the participation of the pa-
tient and the caregivers, while the following sessions
up to the 18th will be provided to clusters of families,
according to a multi-family revised version of family
psychoeducation [28,29].
The GT is a treatment providing general information
on the disorders and with the same frequencies as the FPP
(Table 2). The GT treatment sessions are also provided on
a weekly basis for six months (one and a half hours for each
session). Each GT session is structured in three steps: first,
a short (20 minutes maximum) and hopefully informative
introduction on selected topics concerning the main prob-
lems related to the disorder (see Table 2 for details); then
family members are asked to discuss whether and how they
faced the problem described, whether the solution was
effective and why, and they are then are invited to imagine
alternative solutions to the problem that differ from the
solutions they adopted; finally, a ten-minute conclusion
summarizes the main elements of the topic discussed dur-
ing the meeting. This scheme is specifically effective in
multi-family meetings, when different families are invited
to discuss and compare the problems they faced and the
solutions they adopted, and whether effective or not.
Both treatments share some common, non-specific
effects, while they differ on their specific effects. The basic
strategy in family psychoeducation attempts to reduce the
impact of environmental stress on biologically vulnerable
individuals by promoting communication within the family,
increasing coping skills and improving problem-solving
Table 2 Timing and structure of the planned interventions: Falloon and co-workers’ Psychoeducation Program (FPP)
and Generic Treatment (GT)
Sequence Month FPP GT Type of meeting
1 week 1 Introduction Introduction on schizophrenia Single family
2 week 1 Evaluation of individual family members Meeting on delusions, hallucinations and apathy Single family
3 week 1 Whole family evaluation Meeting on depression, shame and risk of suicide Single family
4 week 1 1. Informative meeting on schizophrenia Meeting on drugs Single family
5 week 2 2. Meeting on drugs Meeting on aggressive behavior Single family
6 week 2 3. Meeting on early signs of relapse Meeting on psycho-social treatments Single family
7 week 2 Practical problem solving 1 Meeting on free time, leisure and school Multi-family
8 week 2 Practical problem solving 2 Meeting on participation in family life Multi-family
9 week 3 Practical problem solving 3 Meeting on early signs of relapse Multi-family
10 week 3 Interpersonal problem solving 1 Meeting on eating habits and obsessions Multi-family
11 week 3 Interpersonal problem solving 2 Meeting on therapy acceptance Multi-family
12 week 3 Interpersonal problem solving 3 Meeting on self-care and somatic health Multi-family
13 week 4 Personal problem solving 1 Meeting on disability Multi-family
14 week 4 Personal problem solving 2 Meeting on stigma Multi-family
15 week 4 Personal problem solving 3 Meeting on legal problems and substance abuse Multi-family
16 week 4 First verification of family changes Meeting on social anxiety Multi-family
First week of the month 5 Second verification of family changes Meeting on social services Multi-family
First week of the month 6 Third verification of family changes Summary meeting and verification of family changes Multi-family
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by: a) providing information about the disorder, which
should also decrease the pathogenic impact of ‘false myths’
concerning the illness; b) the provision of coping strategies
to manage crises; c) the implementation of a more comfort-
able environment where support is provided by peers and
professionals. Within this framework, non-specific effects
include emotional support, empathic listening, and the
implementation of therapeutic optimism. Specific effects,
expected to influence therapeutic outcome, are thought to
be the consequence of specific and well-defined treatment
strategies. In the FPP, the specific effects are thought
to be the consequences of improved problem-solving,
better coping and tolerance to stress, and improved so-
cial skills acquired by the intervention. In the GT, the
specific effects are essentially the reduction of shame
and sense of guilt obtained by explicitly talking about
situational problems related to the disorder, and the
modelization on the non-judgmental, empathic and
supportive behavior of the therapist.
For both the FPP and GT, participation in the meetings
by each family member who has expressed willingness to
participate will be recorded. A family will be considered
adherent to the psychoeducation treatment when at least
one member of the family has participated in 70% of the
meetings (n = 12 out of 18). The rate of family attendance
will be considered as a confounding variable in the
evaluation of outcome. Percentage of drop-out by type
of psychoeducation treatment (families who have notparticipated in three successive meetings and have not
attended at least 70% of meetings overall) will be con-
sidered as an independent measure of applicability of
the method (FPP or GT).
Assessment and outcome measures
Assessment is aimed at investigating the clinical and
functional status of the patients and evaluating the main
effects of treatment on the primary and secondary outcome
measures (Table 3). The primary outcome is the patient’s
adherence to pharmacotherapy, intended as the continuous
use of the primary prescribed drug. Even if patients with
psychosis are generally under poly-pharmacotherapy, only
adherence to the most important drug (the one expected
to produce the main therapeutic effect), as indicated by
the enrolling unit, will be monitored during the study.
Adherence will be checked by a triple method of assess-
ment: patient’s self-report on the Medication Adherence
Rating Scale (MARS), patient’s replies to the four-query
interview of the Brief Adherence Rating Scale (BARS), and
measurement of blood levels of the prescribed drug. Data
will be analyzed using two indicators of adherence:
1. a dichotomic index, where non-adherence is the lack
of adherence to the treatment in 30% or more of the
monthly evaluation on the self-report or the interview
(since replies on both measures might not coincide);
2. a continuous index based on the scale - self-report
or interview - which could be the most reliable by
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the primary prescribed drug, to apply statistical
analyses of covariance and verify the impact of
confounding variables on the primary outcome.
A number of related, secondary outcomes will be
assessed: the occurrence of psychotic symptoms, according
to the Brief Psychiatric Rating Scale (BPRS) and the Positive
and Negative Syndrome Scale (PANSS); the general level
of psychopathology, according to the Health of the Nation
Outcome Scales (HoNOS); changes in social functioning,
according to the Personal and Social Performance scale
(PSP), and in the quality of life, as evaluated on the WHO-
Quality of Life-Short form (WHOQOL-Bref); changes in
the patient’s overall clinical status, as measured by the
Clinical Global Impression (CGI); changes in the dosage
of the prescribed drugs, as a reflection of changes in
adherence to therapy; and, finally, changes in the frequency
of relapse and readmission. Italian validated versions
of the scales will be used. The BARS and the Family
Questionnaire (see below) were translated for this study.
Assessment tools
The MARS is a ten-item yes/no self-report instrument.
Total scores vary from 0 (low likelihood of medication
adherence) to 10 (high likelihood). From this scale, we
used the five items specifically referring to the taking
or not of the medication [31,32]. Therefore in our MARS
version, total scores vary from 0 (low likelihood of
medication adherence) to 5 (high likelihood).
The BARS is a brief, pencil-paper, clinician-administered
adherence assessment instrument [33]. The BARS consistsTable 3 Timing of assessments of endpoints for efficacy and
Background information (age, sex, diagnosis, and so on)
Clinical Global Impressions
Brief Psychiatric Rating Scale (BPRS)
Positive And Negative Syndrome Scale (PANSS)
Social Performance Scale
Health of the Nation Outcome Scales (HoNOS)
World Health Organization Quality Of Life (WHOQoL)
The Family Questionnaire
Medication Adherence Rating Scale
Brief Adherence Rating Scale
Dosage Record and Treatment Emergent Symptoms Scale (DOTES)
Sheenan-Suicidality Tracking Scale (S-STS)
Modified Overt Aggression Scale (MOAS) 1.0
Blood sample for assessing of the blood level of the prescribed drug
Assessment of blindingof four items: three questions and an overall visual analog
rating scale to assess the percentage of doses taken by the
patient in the past month (0% to 100%). The visual analog
scale rating serves as a final adherence determination. The
three questions inquire about patients’ knowledge of their
own medication regimen and episodes of missed medica-
tion taking, and include: number of prescribed doses per
day (question 1); number of days, over the past month, the
patient did not take the prescribed doses (question 2); and
number of days, over the past month, the patient took less
than the prescribed doses (question 3). A higher score on
the BARS corresponds to better adherence.
The CGI is a tripartite rating scale aimed at assessing the
severity of the patient at the moment of the assessment,
improvement or worsening relative to the baseline, and
efficacy of treatment (described in [34]). The CGI-severity
rating is provided on a seven-point scale that assesses
severity of the patient on the basis of total clinical impres-
sion: 1) not at all ill; 2) borderline mentally ill; 3) mildly ill;
4) moderately ill; 5) markedly ill; 6) severely ill; or 7) ex-
tremely ill. The CGI-change is provided on a seven-point
scale, rated as: 1) very much improved; 2) much improved;
3) minimally improved; 4) no change; 5) minimally worse;
6) much worse; or 7) very much worse. The CGI-efficacy
index is a rating scale crossing the efficacy of the treatment
by occurrence of side effects: 1) unchanged to worse; 2)
minimal efficacy; 3) moderate efficacy; 4) marked efficacy,
with side effects rated as: 1) none; 2) does not interfere with
patient’s functioning; 3) interferes with patient’s functioning;
4) outweighs therapeutic effects. A higher score on the
CGI-severity and the CGI-change rating corresponds to
greater severity and worsening, respectively. Conversely,safety
T0 T1 T2 T3
X
X X X X
X X X X
X X X X
X X X X
X X X X
X X X X
X X X X
X X X X
X X X X
X X X X
X X X X
X X X X
X X X X
X
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better efficacy (however, greater side effects counterbalance
efficacy).
The BPRS is a 24-item measure of general psychopath-
ology in a Likert format, with scores from 1 (absent) to 7
(extremely severe) [35,36]. Possible BPRS total scores varied
from 24 to 168. The primary purpose of the BPRS is to
allow assessment of treatment change across a comprehen-
sive set of common symptom characteristics. The original
16-item BPRS was initially expanded to 18 items, then to
24 items by adding 6 symptom items (bizarre behavior,
self-neglect, suicidality, elevated mood, distractibility,
and motor hyperactivity) to increase sensitivity to a broader
range of psychotic and affective symptoms [37]. A higher
score on the BPRS corresponds to greater psychopathology.
The PANSS is a measure of the current symptoms of
patients on a 30-item scale [38,39]. The PANSS consists
of three domains: positive symptoms, negative symptoms,
and general psychopathology. Items are rated from 1
(absent) to 7 (extremely severe); the total score varies from
30 to 210. A higher score on the PANSS corresponds to
greater psychopathology.
The HoNOS comprises 12 items that rate various aspects
of mental and social health with a severity score varying
from 0 (no problem) to 4 (severe to very severe problem).
These items are grouped in four subscales: behavioral
problems, impairment problems, symptoms problems
and social problems [40]. Clinicians rate HoNOS before
and after interventions, so that changes attributable to the
interventions (outcomes) can be measured [41]. A higher
score on each HoNOS subscale corresponds to greater
occurrence of problems in the corresponding areas.
The PSP is a version of the Global Assessment of
Functioning [42], with detailed instructions on how to
rate the functioning of the patient [43]. The PSP rates
the social and occupational functions of patients; its
scores vary from 1 to 100, with a score of 100 indicating
excellent functioning.
The WHOQOL-Bref is a relatively new instrument,
used to measure quality of life. It is an abbreviated version
of the WHOQOL-100 quality of life instrument, developed
by the WHOQOL group [44,45]. The WHOQOL-Bref
adopts the following definition of health-related quality of
life: ‘the value assigned to duration of life as modified by
the impairments, functional states, perceptions, and social
opportunities that are influenced by disease, injury, treat-
ment, or policy’ [46]. It produces scores for four domains
related to the quality of life (physical health, psychological
sphere, social relationships and the environment). The
Italian version used in this study was also reported to have
satisfactory psychometric properties [47]. The items are
rated on a five-point Likert scale, reflecting intensity,
capacity, frequency or evaluation. The items inquire ‘how
much’, ‘how completely’, ‘how often’, ‘how good’ or ‘howsatisfied’, with possible answers varying from ‘very satisfied’
to ‘not at all satisfied’. The scores in each domain vary
from 4 to 20, where a higher score indicates a better
quality of life.
Expressed emotion in the patient’s family
The concept of expressed emotion (EE) was developed
to describe the emotional environment and the attitude
of caregivers towards a relative affected by a disorder. The
Camberwell Family Interview (CFI) is the standard refer-
ence for this type of study [48], and measures the amount
of critical comments (CCs), hostility (H), or emotional
over-involvement (EOI) expressed by a close relative when
talking about a mentally or physically ill family member.
High EE consistently predicts the risk of relapse for patients
with schizophrenia [49,50], but the CFI is time-consuming,
and requires detailed training of the assessors. The Family
Questionnaire (FQ) is a brief self-report questionnaire aimed
at measuring expressed emotion on a four-point Likert
scale, from 0 (never/rarely) to 4 (often/always) [51]. The
FQ provides two subscale scores: critical comments (CC)
and emotional over-involvement (EOI). Scores of 24 or
higher on the CC subscale or 28 or higher on the EOI
subscale define the occurrence of EE in the family. The
FQ was proved to relate to EE rating by the CFI. FQ scores
will be analyzed both as a confounding variable to explore
the role of EE in the effectiveness of psychoeducation, and
as an outcome measure to evaluate whether FPP or GT can
improve EE levels in the patient’s family.
Remission
According to the Remission in Schizophrenia Working
Group, remission for patients with schizophrenia is defined
as a mild score (= 3 or lower) over a six-month period on
all eight items of PANSS considered representative of the
core symptoms of psychosis: delusions, hallucinations,
positive formal thought disorder, bizarre behavior, affective
flattening, avolition-apathy, anhedonia-asociality, alogia;
or a mild score (= 3 or lower) over a six-month period on
all seven items of BPRS considered representative of
the core symptoms of psychosis: grandiosity, suspicious-
ness, unusual thought content, hallucinatory behavior,
conceptual disorganization, mannerism/posturing, blunted
affect [52,53].
Relapse
For the purpose of this study, relapse is defined as any
score equal to five or higher - for one month out of two
or more - on the core symptoms of psychosis on the
BPRS or PANSS, as defined above.
Readmission rate
Readmission is defined as any admission to a psychiatric
unit to treat symptoms of psychosis or to change the drug
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considered as episodes of readmission. All voluntary and
involuntary admissions of participants at enrollment during
the study and at follow-up will be recorded.
Suicidal ideation and suicidal behavior
For the purpose of this study, suicide attempt is defined
as any act of purposeful self-harm with expressed suicidal
intent, that is, the wish to die, as reported by the patient at
the assessment or by a family member consulted as a key
informant (no discrepancy), or recorded during treatment,
within the first year of follow-up. Suicidal ideation will
be measured with the Sheehan Suicidality Tracking Scale
(S-STS). The S-STS is an eight-item prospective rating scale
that tracks treatment-emergent suicidal ideation and behav-
iors [54,55]. Each item in the S-STS is scored on a five-
point Likert scale (0 = not at all, 1 = a little, 2 = moderately,
3 = very, and 4 = extremely). Data from the S-STS can be
analyzed as individual item scores, a suicidal ideation
subscale score (sum of scores from items 2, 3, and 4,
plus score from item 5 if ≥ 1), a suicidal behavior subscale
score (sum of scores from items 6, 7a, and 8, plus score
from item 5 if > 1), and as a total score. A higher score
on the S-STS and its subscales corresponds to greater
risk of suicide.
Aggressive behavior
Aggressive behavior will be monitored with the Modified
Overt Aggression Scale (MOAS). The MOAS rates overt
aggression displayed by the patient in the period preceding
the assessment [56,57]. Ratings are provided for the
most severe act in four categories: verbal aggression,
aggression against objects, aggression against oneself,
and aggression against other people. Aggressive acts are
rated from 0 (no aggressive behavior) to 4, with increasing
severity from 1 to 4; then, scores are multiplied by a fac-
tor specific for each category: 1 for verbal aggression, 2
for aggression against objects, 3 for aggression against
oneself, and 4 for aggression against other people [58].
The total score varies from 0 (no aggression) to 40
(maximum grade of aggression). A higher score on the
MOAS and its subscales corresponds to a higher occur-
rence of aggressive behaviors.
Side effects
Side effects to drugs will be closely monitored and
coded with the Dosage Record and Treatment Emergent
Symptoms Scale (DOTES). The DOTES is a 30-item scale
aimed at recording changes in the patient’s health status
that can or could be attributed to the prescribed psycho-
pharmacological treatment (described in [34]). The scale
lists symptoms and pathological conditions affecting the
patient’s body, with a judgment required on their presence
and severity, and a separate assessment of the actual orpotential links with the patient’s prescribed drugs. The
presence and severity subscale includes 4 levels, from 1
(absent) to 4 (severe, resulting in drug suspension).
The subscale on the actual or potential links with the
patient’s prescribed drugs includes 5 levels, from 1
(symptom absent or no link), to 5 (certain link, as certified
in the literature). A higher score on the DOTES corre-
sponds to a higher occurrence and severity of side effects,
which may or may not be related to the patient’s prescribed
drugs on the basis of the rating of the subscale on the
actual or potential links.
Follow-up assessment
The FPP has a six-month duration, so patients will be
assessed at entry (t0), at the end of the FPP (t1), at the six-
month follow-up (t2), and at the twelve-month follow-up
(t3), for secondary outcome measures. Adherence will be
monitored at t0, t1, t2, and t3, via self-reports, interviews
and measured blood levels of the primary prescribed drug.
Sample size and power
Sample size for the identification of the expected difference
in the primary outcome (adherence to pharmacotherapy)
was based on known evidence: prevalence of non-adherence
to pharmacotherapy in patients already in contact with
a psychiatric service is around 40 to 50%, median = 47%
[11,12]; effect size of psychosocial treatment on various
outcomes, including relapse, readmission and adherence
to pharmacotherapy is 0.48 of the standard deviation
(SD), with 95% CI= 0.10 to 0.85 [16]. We expect that our
intervention could produce a change in the prevalence of
non-adherence to pharmacotherapy in the exposed group
with an effect size of 0.45 SD [11,12]. After performing a
test of difference between proportions we determined that
a sample of 78 participants per group would be needed
to achieve 80% power to detect a difference with h = 0.45
(medium effect size) in the measures of adherence to
pharmacotherapy, at a two-sided significance level of 0.05
and allocation ratio of 1:1.
Cohen’s h effect size for the difference of proportions
is calculated on the formula:
h ¼ 2arcsin p1−2arcsin p2
where p1 and p2 are the proportions of adherent patients
in the exposed group 1 and the non-exposed group 2,
respectively [59]. The Cohen’s h measures the same effect
size interval as the Cohen’s d but is based on differences
by proportion rather than by continuous variables [59].
Cohen’s h = 0.45 implies that at the estimated power
(= 80%) we can observe a 25.5% rate of non-adherence
to pharmacotherapy in the exposed group as opposed to
a 47% rate in the unexposed group. In this case, risk re-
duction is 0.215, corresponding to a number needed to
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portion of non-adherence, here are the different starting
p1 and related maximum p2 detectable:
p1: 0.65 0.60 0.55 0.50 0.45 0.40 0.35 0.30 0.25
p2: 0.43 0.38 0.33 0.28 0.24 0.20 0.16 0.12 0.09
Since this a multisite study, the clusterized nature of the
data has to be controlled since it has an impact on an un-
equal variance by center, which requires a correction of the
sample according to the formula:
DE ¼ 1þ m−1ð Þ  r
where m is the original sample size per cluster (in our
study, m = 7.8 + 7.8 = 15.6 about 16), r is a value sum-
marizing the intra-cluster correlation coefficient (ICC),
and DE (design effect) is the correction needed to main-
tain the same effect size in the expected change produced
by the treatment [60]. In most studies, the ICC varies be-
tween 0.02 and 0.05. With ten enrolling units, precaution-
ary ICC equals 0.05 and DE 1 + (16–1)*0.05 = 1.75.
Therefore, by multiplying the initial sample size (n =
156) by DE, the final ICC-corrected sample size is 273,
equal to 27.3 about 28 patients per cluster.
Medication
The study is open about the psychopharmacological
treatment, with no treatment restrictions. On the basis
of the study’s sample size, we expect equal distribution
of type (classical versus atypical antipsychotics), dose,
rate of non-adherence to medication, and prescription
of other psychopharmacological treatment (antidepressants,
mood stabilizers, benzodiazepines) in both treatment
groups. Since the type and medication dose are potential
confounders, they will be controlled.
Data management and analysis
All analyses will be based, as far as possible, on the
intention-to-treat principle. Differences in the primary
outcome (adherence to pharmacotherapy) will be analyzed
with a two-tail test for proportions with the Miettinen exact
test [61]. A multiple logistic regression will be carried out
to control for the confounding variables [62] using adher-
ence (yes/no) as the outcome to verify the impact of the
FPP on controlling the impact of the confounding variables
(sex, age, severity of the disorder, cluster).
Survival analyses will be performed using the Kaplan-
Meier method, followed by the log-rank test to define the
terminal events at both the start of non-adherence and the
first relapse or readmission episode [63]. Intention-to-treat
will be applied considering the primary and secondary
outcomes [64]. Multiple imputations will be applied to
integrate missing data [65].As far as validation of the self-report (MARS) and the
interview (BARS) measure of adherence with respect to
the blood levels of the main prescribed drug is concerned,
Spearman’s rho will be used to compare blood levels of
the main drug with the self-report or the interview; partial
correlation will be used to ascertain the links between
blood levels of the main drug with the self-report or the
interview by taking into account the other measures
(the interview or the self-report, respectively).
All analyses will be done with Excel (Microsoft Excel
2013 running on Windows 8) (Chicago, IL 60606, USA)
or the Statistical Package for Social Science (SPSS) version
17 for Windows.
Ethical considerations
The FPP is not expected to produce relevant somatic side
effects but it can produce unwanted or unforeseen effects,
such as an increase in the intra-family level of conflict. To
maximize safety for the patients, before randomization each
patient will be evaluated on his or her risk of unwanted or
unforeseen effects attributable to exposure to the FPP.
The therapists involved in the administration of the
FPP and GT will be monitored to minimize any improper
method of administration of the protocol of treatment;
assessors will also be trained and monitored to avoid
dispersion of information, thus violating the guaranteed
criterion of good faith in case of patients’ disclosing sensi-
tive information. Data recording and storage will comply
with the privacy law in force, and informed consent for in-
formation recording will be obtained from each patient.
Participation in the study is voluntary and written in-
formed consent is obtained. Before enrollment, participants
will receive both verbal and written assurance that they can
withdraw from the trial any time, with no consequence for
their continued treatment. Patients unable to give informed
consent in an appropriate way or who refuse to participate
in the study will not be enrolled.
The Training Center is committed to monitoring the
quality of assessment and of the administration of the
FPP procedures, on a three-month basis.
A paradoxical, unintended effect of greater adherence
to pharmacotherapy is the potential increase of the som-
atic side effects of the prescribed drugs. Indeed, there is
some indirect evidence that this can actually occur [66].
To limit this paradoxical effect, patients will be closely
monitored for side effects and somatic conditions on a
three-month basis or as needed. It is expected that,
following improvement in the response to the therapy
as a result of greater adherence to pharmacotherapy,
the therapist will decrease dosage of the prescribed
drugs. This specific change will be checked at assessment
and a reduction of dosage of the prescribed drugs and of
poly-pharmacotherapy is among the secondary outcomes
of the study.
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the responsibility of the enrolling unit, and all data are
recorded anonymously and coded with a concealed script,
which will not be disclosed until the end of the study. Only
the Coordination Center owns these concealed codes, not
to be disclosed to the statistical units, which will receive the
data with a neutral assignment (group A, group B).
Safety
Safety will be closely monitored. Key endpoints will be:
 death caused by suicide
 suicide attempt
 suicidal crisis (explicit plan for serious suicidal
activity without suicide attempt)
 severe symptomatic exacerbation, defined by the
Clinical Global Impression Scale (CGI), which
includes ratings of illness severity and changes in
overall clinical status. A rating of CGI-severity ≥ 6
(severely ill) and CGI-change ≥ 3 (much worse)
would be regarded as severe symptomatic
exacerbation.
Information about these safety variables is recorded
in the Case Report Form (CRF) as part of the regular
clinical assessment.
Discussion
To the best of the authors’ knowledge, this is the first
study in Italy concerning the implementation of a protocol
of family psychoeducation within the framework of the
National Health System. Positive findings, if any, might be
extended and generalized to the whole National Health
System, which is an advantage over past studies. Indeed,
past studies principally involved specialized academic
settings [21,67], or included small samples in very specific
settings [68]. In the past, limited benefit was reported in the
routine clinical practice ([27], even though a different view
was expressed by Rummel-Kluge and Kissling [17]).
Another advantage of this study over past investigations
is its sample size, which is planned to be large enough to
allow multivariable analyses to discover specific factors
involved in the effectiveness of psychoeducation, and to
control for confounding factors and covariates. Finally, the
study checks adherence to therapy as the main outcome
measure using both self-report and interview on the one
hand, and blood levels of the main prescribed drug on the
other hand. This will prevent a biased measurement of
adherence to therapy which can occur with subjective
measures like self-report and interviews.
Another important point is the use of a control group
based on a different approach to psychoeducation. This
will allow for the evaluation of the most specific effects
of the FPP, its effectiveness and specificity. We cannotexclude that the GT approach could result as effective as
the FPP in improving adherence to treatment and in de-
creasing relapse and readmission over time. Since we do
not have a third study group on standard care because of
budget limits, we will be unable to establish whether the
changes produced by FPP or GT are really superior to the
changes that can be produced by standard care over time.
Equal effectiveness also points towards superiority of the
less expensive and time-consuming method - the GT -
which might be preferred over the FPP since its imple-
mentation requires less therapist training. A proper eco-
nomic analysis is necessary to assess superiority of one
method over the other in case of equal effectiveness.
Potential limitations
The study protocol imposes a detailed assessment of
symptoms and patient’s functioning, and patients’ will-
ingness to be assessed in such a detailed manner could
be limited. Calculation of sample size included a 20%
drop-out rate. Because of the complexity of the assessment
protocol, dropouts might be more than 20%, thus hamper-
ing the extent of the multivariable analyses on the whole
sample. Patients could also refuse blood sampling and not
permit the main gold standard of adherence measurement.
Trial status
The study started recruiting participants in February
2013, and the recruitment is ongoing.
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